Zurnai (autoinjector) is a drug owned by Purdue Pharma Lp. It is protected by 21 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 05, 2039. Details of Zurnai (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11865112 | Compositions and methods for opioid antagonist delivery |
Nov, 2039
(14 years from now) | Active |
| US11857547 | Compositions and methods for opioid antagonist delivery |
Nov, 2039
(14 years from now) | Active |
| US11191908 | Syringe shock absorber for use in an injection device |
Oct, 2035
(10 years from now) | Active |
| US11813435 | Needle assisted injection device having reduced trigger force |
Feb, 2035
(10 years from now) | Active |
| US10881798 | Needle assisted injection device having reduced trigger force |
Feb, 2034
(9 years from now) | Active |
| US11185642 | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | Active |
| US9364610 | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | Active |
| US9446195 | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | Active |
| US10357609 | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(6 years from now) | Active |
| US11446440 | Needle assisted injection device having reduced trigger force |
Aug, 2031
(6 years from now) | Active |
| US8496619 | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | Active |
| US9364611 | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(6 years from now) | Active |
| US10905827 | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | Active |
| US10279131 | Injection device with cammed RAM assembly |
Jul, 2031
(6 years from now) | Active |
| US8021335 | Prefilled syringe jet injector |
Oct, 2026
(1 year, 9 months from now) | Active |
| US8562564 | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | Active |
| US9533102 | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | Active |
| US9629959 | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | Active |
| US10478560 | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | Active |
| US9180259 | Prefilled syringe jet injector |
Jan, 2026
(1 year, 1 month from now) | Active |
| US11446441 | Prefilled syringe injector |
Jan, 2026
(1 year, 1 month from now) | Active |
FDA has granted several exclusivities to Zurnai (autoinjector). Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zurnai (autoinjector), regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zurnai (autoinjector).
Exclusivity Information
Zurnai (autoinjector) holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Zurnai (autoinjector)'s exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Several oppositions have been filed on Zurnai (autoinjector)'s European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Zurnai (autoinjector)'s generic, the next section provides detailed information on ongoing and past EP oppositions related to Zurnai (autoinjector) patents.
Zurnai (autoinjector)'s Oppositions Filed in EPO
Zurnai (autoinjector) has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 07, 2019, by Bandpay & Greuter. This opposition was filed on patent number EP06719329A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19150366A | Sep, 2022 | Bandpay & Greuter | Granted and Under Opposition |
| EP06719329A | Oct, 2019 | Bandpay & Greuter | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Zurnai (autoinjector) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zurnai (autoinjector)'s family patents as well as insights into ongoing legal events on those patents.
Zurnai (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zurnai (autoinjector)'s generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 05, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zurnai (autoinjector) Generic API suppliers:
Nalmefene Hydrochloride is the generic name for the brand Zurnai (autoinjector). 2 different companies have already filed for the generic of Zurnai (autoinjector), with Chengdu Shuode having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zurnai (autoinjector)'s generic
Alternative Brands for Zurnai (autoinjector)
There are several other brand drugs in the same treatment category and using the same active ingredient (Nalmefene Hydrochloride) as Zurnai (autoinjector). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Indivior |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Nalmefene Hydrochloride, Zurnai (autoinjector)'s active ingredient. Check the complete list of approved generic manufacturers for Zurnai (autoinjector)
About Zurnai (autoinjector)
Zurnai (Autoinjector) is a drug owned by Purdue Pharma Lp. Zurnai (Autoinjector) uses Nalmefene Hydrochloride as an active ingredient. Zurnai (Autoinjector) was launched by Purdue Pharma Lp in 2024.
Approval Date:
Zurnai (autoinjector) was approved by FDA for market use on 07 August, 2024.
Active Ingredient:
Zurnai (autoinjector) uses Nalmefene Hydrochloride as the active ingredient. Check out other Drugs and Companies using Nalmefene Hydrochloride ingredient
Dosage:
Zurnai (autoinjector) is available in solution form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML) | SOLUTION | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |